The Challenge

Regulatory & Compliance as a Bottleneck

Healthcare innovation is moving at a faster rate than many regulatory processes. Drug approvals, reimbursement frameworks, and market access evaluations can be labor-intensive and time-consuming.

Demand for Comprehensive Economic and Budget Impact Analysis

Pharmaceutical, payer, and public health organizations need robust models to predict costs and outcomes. They require evidence-based modeling for decisions on pricing, coverage, or policy-making.

Fragmented Tools & Data Sources

Some analysts rely on Excel, R, or specialized software that can be siloed, difficult to share, and not transparent to multiple stakeholders. Handling large real-world datasets is also cumbersome without a unified platform.

High Consulting Costs & Slow Turnaround

Traditional HEOR consulting engagements can be costly and take months for a single model. An automated, productized approach can reduce both cost and time.

Market Opportunity

• Regulatory bodies are increasingly accepting real-world evidence (RWE) alongside clinical trial data. There is a need for platforms that can integrate real-world datasets, conduct rapid analyses, and present cost-effectiveness or budget impact results.
• There is strong VC interest in digital health AI; for instance, 44% of digital health funding in 2024 was directed towards AI-focused companies (reference: DHNY Summit 2024).
• The ISPOR "Top 10 HEOR Trends" shows a rapid increase in AI adoption for outcomes research. This environment is ideal for an AI-enabled HEOR platform like SuperModel.